Expanding the Armamentarium for Castrate-resistant Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2016.05.022
Abstract: Castrate-resistant prostate cancer (CRPC) is an incurable clinical condition that accounts for the vast majority of the >300 000 recorded deaths from this disease each year across the globe. This high level of mortality is… read more here.
Keywords: prostate cancer; disease; castrate resistant; cancer ... See more keywords
Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development.
Sign Up to like & getrecommendations! Published in 2017 at "ACS chemical biology"
DOI: 10.1021/acschembio.6b01035
Abstract: There is a tremendous need for novel strategies aimed at directly assessing activities of histone modifiers to probe epigenetic determinants associated with disease progression. Here, we developed a high-throughput peptide microarray assay to identify altered… read more here.
Keywords: activity; castrate resistant; prostate cancer; histone ... See more keywords
Effect of Dietary Omega-3 Fatty Acids on Castrate Resistant Prostate Cancer and Tumor Associated Macrophages
Sign Up to like & getrecommendations! Published in 2019 at "Prostate cancer and prostatic diseases"
DOI: 10.1038/s41391-019-0168-8
Abstract: Background M2-like macrophages are associated with the pathogenesis of castrate-resistant prostate cancer (CRPC). We sought to determine if dietary omega-3 fatty acids (ω-3 FAs) delay the development and progression of CRPC and inhibit tumor-associated M2-like… read more here.
Keywords: prostate cancer; omega fatty; dietary omega; castrate resistant ... See more keywords
Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/srep40957
Abstract: Androgen receptor variants (AR-Vs) provide a mechanism of therapy evasion in castrate-resistant prostate cancer (CRPC), yet mechanisms of regulation remain largely unknown. Here we investigate the role of Aurora A kinase on AR-Vs in models… read more here.
Keywords: crpc; resistant prostate; castrate resistant; prostate cancer ... See more keywords
Cardiovascular, bone, and metabolic health in men with castrate-resistant prostate cancer treated with androgen deprivation: a matched cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2022.2141077
Abstract: Abstract Background Descriptive data on late effects associated with castrate-resistant prostate cancer (CRPC) are sparse. We aimed to define the timing and incidence of cardiovascular disease (CVD), fractures, and diabetes in a patient population with… read more here.
Keywords: incidence; castrate resistant; prostate cancer; resistant prostate ... See more keywords
Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect?
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000001807
Abstract: Two patients with castrate-resistant prostate cancer and symptomatic skeletal metastases underwent F-fluorocholine PET/CT prior to treatment with Ra-dichloride to reveal additional active lesions in the prostate gland and lymph nodes. Subsequent scans performed at the… read more here.
Keywords: soft tissue; fluorocholine pet; prostate cancer; tissue ... See more keywords
Metastatic castrate-resistant prostate cancer: a new horizon beyond the androgen receptors
Sign Up to like & getrecommendations! Published in 2022 at "Current Opinion in Supportive and Palliative Care"
DOI: 10.1097/spc.0000000000000620
Abstract: Purpose of review Systemic chemotherapy and second-generation androgen receptor-axis targeted therapies have been in the forefront of management for metastatic castrate-resistant prostate cancer (mCRPC) patients with low or high symptom burden. However, in the recent… read more here.
Keywords: castrate resistant; metastatic castrate; prostate; resistant prostate ... See more keywords
Abstract 5389: A personalized medicine approach to identifying dysregulated epigenetic enzyme activity in the development of castrate-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-5389
Abstract: Purpose: Recent advances in proteomic and chromatin immunoprecipitation tools have been vital in studying cancer epigenetics, but the ability to measure directly the enzyme activities of dysregulated histone-modifiers understudied. We utilize a novel approach to… read more here.
Keywords: medicine; resistant prostate; castrate resistant; approach ... See more keywords
Abstract PR005: CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition
Sign Up to like & getrecommendations! Published in 2024 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1538-8514.synthleth24-pr005
Abstract: Monotherapy with PARP inhibitors is effective for the subset of castrate-resistant prostate cancer (CRPC) with defects in homologous recombination (HR) DNA repair. New treatments are required for the remaining tumors, and an emerging strategy is… read more here.
Keywords: dna damage; cancer; parp; resistant prostate ... See more keywords
Trop-2 expression on treatment resistant cancer cells in castrate-resistant prostate cancer (CRPC) as a predictive biomarker for targeted therapy.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.5045
Abstract: 5045Background: Trophoblastic cell-surface antigen (Trop-2) is a transmembrane glycoprotein that is highly expressed in many solid tumors. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate of an anti-Trop-2 humanized antibody with SN-38. Early clinical trials have… read more here.
Keywords: trop expression; prostate cancer; expression; castrate resistant ... See more keywords
Cabazitaxel in metastatic castrate resistant prostate cancer (mCRPC) in the era of enzalutamide (ENZA) and abiraterone acetate (AA).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e16517
Abstract: e16517Background: The concurrent development of cabazitaxel, AA, ENZA, and radium-223 has recently increased the number of therapeutic options for mCRPC. Cabazitaxel is currently approved for mCRPC... read more here.
Keywords: cabazitaxel; metastatic castrate; prostate cancer; castrate resistant ... See more keywords